|
EQS-Ad-hoc: Viromed Medical AG / Key word(s): Alliance Viromed Medical AG seeks extensive cooperation with a major global Group Pinneberg, 11 December 2024 - Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; ‘Viromed’; the ‘Company’) is seeking an extensive cooperation with a major global Group that is also active in the pharmaceutical sector. Based on today's discussions, the subject of the cooperation will be in particular the granting of a worldwide licence in favour of Viromed Medical AG for the application of cold atmospheric pressure plasma in medicine. Subject to a contractual agreement, which is expected within the next three months, Viromed expects to generate initial revenues from the use of cold atmospheric pressure plasma in the low double-digit million range as early as the second half of the 2025 financial year. Another subject of the negotiations for the establishment of an extensive cooperation is a possible participation of the global Group in Viromed or, conversely, a participation of Viromed in portfolio companies of the global Group. However, decisive negotiations on the essential terms of the respective participations are still pending. Viromed will inform the capital market about the further progress of the negotiations on the intended cooperation in accordance with its legal obligation.
Contact Viromed Medical AG
End of Inside Information
11-Dec-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Viromed Medical AG |
| Flensburger Straße 18 | |
| 25421 Pinneberg | |
| Germany | |
| Phone: | +49 4101 809960 |
| E-mail: | kontakt@viromed-medical.de |
| Internet: | https://www.viromed-medical-ag.de/ |
| ISIN: | DE000A3MQR65 |
| WKN: | A3MQR6 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt (Basic Board), Hamburg |
| EQS News ID: | 2049425 |
| End of Announcement | EQS News Service |
|
|
2049425 11-Dec-2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
Special
